Paradromics advances MGH clinical study and announces new research platform with five partner institutions
Summary
Paradromics advanced their Connect-One clinical study at Massachusetts General Hospital under PI Leigh Hochberg and simultaneously announced a new research platform with five new institutional partners in March 2026, as reported in Neurotech Notables #51. The five-partner research platform will provide academic sites access to Connexus BCI hardware for research studies outside the core clinical trial protocol, building the clinical research ecosystem around the high-bandwidth neural interface technology while the pivotal path proceeds at MGH. Neuralink and Science Corporation also hired key clinical leaders in the same period, reflecting coordinated talent acquisition across the BCI sector.
Why it matters
Paradromics building a five-partner research platform alongside their clinical trial is the academic ecosystem strategy that generates publications, trains investigators, and builds the clinical community that commercial BCI success requires. Universities and hospitals that use Connexus for research become the natural first commercial adopters — research platform partnerships create pre-commercial relationships that convert to commercial accounts when FDA clearance is obtained.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial